0001139685-16-000008.txt : 20160219 0001139685-16-000008.hdr.sgml : 20160219 20160219141207 ACCESSION NUMBER: 0001139685-16-000008 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20160219 DATE AS OF CHANGE: 20160219 EFFECTIVENESS DATE: 20160219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 20/20 GeneSystems, Inc. CENTRAL INDEX KEY: 0001139685 IRS NUMBER: 522272107 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-247978 FILM NUMBER: 161441321 BUSINESS ADDRESS: STREET 1: 9430 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 2404536339 MAIL ADDRESS: STREET 1: 9430 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: 20/20 GENE SYSTEMS INC DATE OF NAME CHANGE: 20010502 D/A 1 primary_doc.xml X0707 D/A LIVE 0001139685 20/20 GeneSystems, Inc. 9430 KEY WEST AVENUE SUITE 100 ROCKVILLE MD MARYLAND 20850 2404536339 DELAWARE 20/20 GENE SYSTEMS INC Corporation true Jonathan Cohen 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Executive Officer Director President, CEO and Director Joel Kanter 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Executive Officer Director Donald Wallach 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Director Vladimir Knezevic 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Director Dean Hautamaki 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Director Caroline Popper 9430 Key West Avenue Suite 100 Rockville MD MARYLAND 20850 Director Biotechnology Decline to Disclose 06c true 0001139685-15-000006 2014-10-31 true true true true false 5000 Zacks Investment Bank None LBMZ Securities, Inc. 7874 10 S. Riverside Plaza Suite 1600 Chicago IL ILLINOIS 60606 All States false 4000000 2513413 1486587 false 66 37100 true 0 Estimate of commissions for Offering to date. 0 true A portion of the proceeds of the offering may in the future be used as part of the compensation package for certain of the issuer's executive officers in the form of cash or equity. false 20/20 GeneSystems, Inc. /s/ Jonathan Cohen Jonathan Cohen President & CEO 2016-02-19